Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth ...

Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC; Serplulimab is the first and only anti-PD-1 mAb approved in th ...

Kotak Alternate Asset Managers Ltd, the alternative asset management arm of Kotak Mahindra Group, said Thursday it has ...

and serving as Vice President for Intas Pharmaceuticals Ltd. His career spans over two decades, marked by significant contributions to revenue growth and market expansion in the pharmaceutical sector.

Detailed price information for Sunshine Biopharma (SBFM-Q) from The Globe and Mail including charting and trades.

London-headquartered Accord is one of the largest suppliers of chemotherapy products in Europe and is a wholly-owned subsidiary of India's Intas Pharma, which has annual revenues of around $3.4 ...

Madurai/Trichy: Doctors have urged the Union govt to make cancer a notifiable disease to track trends in cases and improve ...

RALEIGH, N.C., Jan. 16, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of ...

Sun Pharma maintained market leadership, while Emcure and Torrent advanced to 10th and 16th positions, respectively. Top performers included Alkem, Aristo, Intas, Torrent, Cipla, and FDC, all ...

Accord-UK – as well as parent companies Intas, Accord and former parent Allergan ... by the CMA as part of a clampdown on the pharma sector, including a probe of the price of antidepressants ...